Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation

Transplant Proc. 2002 Nov;34(7):2777-8. doi: 10.1016/s0041-1345(02)03409-7.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Benzimidazoles / therapeutic use
  • Cytochrome P-450 CYP2C19
  • Drug Interactions
  • Famotidine / therapeutic use
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / physiology*
  • Lansoprazole
  • Male
  • Middle Aged
  • Mixed Function Oxygenases / genetics*
  • Omeprazole / analogs & derivatives
  • Omeprazole / therapeutic use
  • Proton Pump Inhibitors*
  • Rabeprazole
  • Tacrolimus / therapeutic use*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Immunosuppressive Agents
  • Proton Pump Inhibitors
  • Lansoprazole
  • Rabeprazole
  • Famotidine
  • Mixed Function Oxygenases
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Omeprazole
  • Tacrolimus